Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages 5422-5427

  Divakaruni, Ajit S ^a   Wiley, Sandra E ^a   Rogers, George W ^b   Andreyev, Alexander Y ^a   Petrosyan, Susanna ^a   Loviscach, Mattias ^c   Wall, Estelle A ^a   Yadava, Nagendra ^d   Heuck, Alejandro P ^e   Ferrick, David A ^b   Henry, Robert R ^a,c   McDonald, William G ^f   Colca, Jerry R ^f   Simon, Melvin I ^a   Ciaraldi, Theodore P ^a,c   Murphy, Anne N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Seahorse Bioscience   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d Pioneer Valley Life Sciences Institute   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f Metabolic Solutions Development Company   (United States)

Author keywords

AMPK; MSDC 0160; Pioglitazone; Rosiglitazone; XF PMP

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CARRIER PROTEIN; CYTOLYSIN; GLUCOSE; MITOCHONDRIAL PYRUVATE CARRIER; PIOGLITAZONE; PYRUVIC ACID; ROSIGLITAZONE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL MEMBRANE PERMEABILITY; CELL TYPE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; GENE SILENCING; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; IC 50; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIROMETRY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; WESTERN BLOTTING;

ACRYLATES; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL RESPIRATION; CYTOCHROMES C; GLUCOSE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE TRANSPORT PROTEINS; METABOLIC NETWORKS AND PATHWAYS; MICE; MITOCHONDRIAL MEMBRANES; MITOCHONDRIAL PROTEINS; MUSCLE, SKELETAL; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES;

MAMMALIA;

EID: 84875858252     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303360110     Document Type: Article

References (57)

1. Divakaruni AS, Murphy AN (2012) Cell biology: A mitochondrial mystery, solved. Science 337(6090):41-43.
2. Papa S, Francavilla A, Paradies G, Meduri B (1971) The transport of pyruvate in rat liver mitochondria. FEBS Lett 12(5):285-288.
3. Halestrap AP, Denton RM (1974) Specific inhibition of pyruvate transport in rat liver mitochondria and human erythrocytes by alpha-cyano-4- hydroxycinnamate. Biochem J 138(2):313-316.
4. Herzig S, et al. (2012) Identification and functional expression of the mitochondrial pyruvate carrier. Science 337(6090):93-96.
5. Bricker DK, et al. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337(6090):96-100.
6. DeFronzo RA, Abdul-Ghani MA (2011) Preservation of β-cell function: The key to diabetes prevention. J Clin Endocrinol Metab 96(8):2354-2366.
7. Cunnane S, et al. (2011) Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27(1):3-20.
8. Colmers IN, Bowker SL, Johnson JA (2012) Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab 38(6): 475-484.
9. Miller BW, Willett KC, Desilets AR (2011) Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann Pharmacother 45(11):1416-1424.
10. Colca JR, Kletzien RF (2006) What has prevented the expansion of insulin sensitisers? Expert Opin Investig Drugs 15(3):205-210.
11. Graham DJ, et al. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304(4):411-418.
12. Lehmann JM, et al. (1995) An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270(22):12953-12956.
13. Choi JH, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466(7305):451-456.
14. Norris AW, et al. (2003) Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112(4): 608-618.
15. Feinstein DL, et al. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol 70(2):177-188.
16. LeBrasseur NK, et al. (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291(1): E175-E181.
17. Wei S, Kulp SK, Chen CS (2010) Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem 285(13):9780-9791.
18. Birnbaum Y, Long B, Qian J, Perez-Polo JR, Ye Y (2011) Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner. Basic Res Cardiol 106(3):431-446.
19. Thal SC, et al. (2011) Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms. J Neurotrauma 28(6): 983-993.
20. Chen Z, et al. (2012) Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem 287(28):23537-23548.
21. Eckland DA, Danhof M (2000) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108(Suppl 2):S234-S242.
22. Kirchheiner J, et al. (2006) Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 80(6):657-667.
23. Brunmair B, et al. (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: A common mechanism contributing to their antidiabetic actions? Diabetes 53(4):1052-1059.
24. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y (2007) Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 223(3):277-287.
25. Schulz I (1990) Permeabilizing cells: Some methods and applications for the study of intracellular processes. Methods Enzymol 192:280-300.
26. Ramachandran R, Heuck AP, Tweten RK, Johnson AE (2002) Structural insights into the membrane-anchoring mechanism of a cholesterol-dependent cytolysin. Nat Struct Biol 9(11):823-827.
27. Heuck AP, Moe PC, Johnson BB (2010) The cholesterol-dependent cytolysin family of gram-positive bacterial toxins. Subcell Biochem 51:551-577.
28. Sanyal S, Claessen JH, Ploegh HL (2012) A viral deubiquitylating enzyme restores dislocation of substrates from the endoplasmic reticulum (ER) in semi-intact cells. J Biol Chem 287(28):23594-23603.
29. Halestrap AP (1975) The mitochondrial pyruvate carrier: Kinetics and specificity for substrates and inhibitors. Biochem J 148(1):85-96.
30. Watkins PB, Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. N Engl J Med 338(13):916-917.
31. Colca JR, et al. (2013) Clinical proof of concept with MSDC-0160, a prototype mTOT modulating insulin sensitizer. J Clin Pharm Ther 93: in press.
32. Hildyard JC, Ammälä C, Dukes ID, Thomson SA, Halestrap AP (2005) Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier. Biochim Biophys Acta 1707(2-3):221-230.
33. Lee MK, Olefsky JM (1995) Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44(9):1166-1169.
34. Fryer LG, Parbu-Patel A, Carling D (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277(28):25226-25232.
35. Coletta DK, et al. (2009) Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: A randomised trial. Diabetologia 52(4):723-732.
36. Hawley SA, et al. (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11(6):554-565.
37. Moe PC, Heuck AP (2010) Phospholipid hydrolysis caused by Clostridium perfringens a-toxin facilitates the targeting of perfringolysin O to membrane bilayers. Biochemistry 49(44):9498-9507.
38. Colca JR, et al. (2004) Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286(2):E252-E260.
39. Halestrap AP (2012) The mitochondrial pyruvate carrier: Has it been unearthed at last? Cell Metab 16(2):141-143.
40. Brivet M, et al. (2003) Impaired mitochondrial pyruvate importation in a patient and a fetus at risk. Mol Genet Metab 78(3):186-192.
41. Stang M, Wysowski DK, Butler-Jones D (1999) Incidence of lactic acidosis in metformin users. Diabetes Care 22(6):925-927.
42. Natali A, Ferrannini E (2006) Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review. Diabetologia 49(3):434-441.
43. Bajaj M, et al. (2010) Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95(4):1916-1923.
44. Teranishi T, et al. (2007) Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 56(10):1418-1424.
45. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM (2006) Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55(8):2277-2285.
46. Cha BS, et al. (2005) Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab 289(1): E151-E159.
47. Dello Russo C, et al. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278(8): 5828-5836.
48. Guan KL, Xiong Y (2011) Regulation of intermediary metabolism by protein acetylation. Trends Biochem Sci 36(2):108-116.
49. Ruderman N, Prentki M (2004) AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3(4):340-351.
50. Friedrichsen M, Mortensen B, Pehmøller C, Birk JB, Wojtaszewski JF (2013) Exerciseinduced AMPK activity in skeletal muscle: Role in glucose uptake and insulin sensitivity. Mol Cell Endocrinol 366(2):204-214.
51. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP (1995) Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects: Comparison using human skeletal muscle cell cultures. Diabetes 44(8):936-946.
52. Rubio M, et al. (2009) Cardioprotective stimuli mediate phosphoinositide 3-kinase and phosphoinositide dependent kinase 1 nuclear accumulation in cardiomyocytes. J Mol Cell Cardiol 47(1):96-103.
53. Cannon B, Nedergaard J (2001) Respiratory and thermogenic capacities of cells and mitochondria from brown and white adipose tissue. Methods Mol Biol 155:295-303.
54. Kushnareva YE, Wiley SE, Ward MW, Andreyev AY, Murphy AN (2005) Excitotoxic injury to mitochondria isolated from cultured neurons. J Biol Chem 280(32): 28894-28902.
55. Chappell JB, Hansford RG (1972) Preparation of mitochondria from animal tissues and yeasts. Subcellular Components: Preparation and Fractionation, ed Birnie GD (Butterworths, London), pp 77-91.
56. Ciaraldi TP, Abrams L, Nikoulina S, Mudaliar S, Henry RR (1995) Glucose transport in cultured human skeletal muscle cells: Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 96(6): 2820-2827.
57. Colca JR, et al. (2013) Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT) - relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One, in press.